Limits On 'Orphan Drug' Tax Credit Face Pushback In Senate
A House-passed plan to raise revenue for Democratic priorities by limiting tax breaks for so-called orphan drugs used to treat rare diseases faces Senate hurdles as allies of the pharmaceutical industry...To view the full article, register now.
Already a subscriber? Click here to view full article